NASDAQ · Biotechnology

EPRX (EPRX) Stock

$7.50 +0.67% NASDAQ: EPRX Healthcare

Valuation

MetricValue
Price$7.50
Market Cap$251.10M
P/E Ratio-7.36
P/B Ratio3.80
P/S Ratio0.00
EPS (TTM)$-1.05
52-Week High$9.32
52-Week Low$5.15
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-45.29%
ROA-35.72%
ROCE-43.18%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio14.17

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-18.0M$-18.0M$-21.0M$-27.0M$-38.0M
Net Profit$-24.0M$-18.0M$-21.0M$-26.0M$-39.0M
EPS$-1.93$-0.96$-0.88$-0.76$-1.03
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$31.0M$26.0M$15.0M$35.0M$86.0M
Total Liabilities$12.0M$16.0M$15.0M$3.0M$6.0M
Cash$21.0M$25.0M$15.0M$33.0M$81.0M
Borrowings$10.0M$12.0M$8.0M$0$0

Latest News

Eupraxia Pharmaceuticals Announces Executive Leadership Changes MT Newswires · Jul 13, 2026 Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth GlobeNewswire · Jul 13, 2026 Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization GlobeNewswire · Jul 7, 2026 Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders GlobeNewswire · Jun 19, 2026 Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference GlobeNewswire · May 28, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-12.0M$-14.0M$-16.0M$-30.0M$-29.0M
Investing Cash Flow$-12.0M$10.0M$0$0$-1.0M
Financing Cash Flow$0$0$4.0M$0$0
Net Cash Flow$16.0M$6.0M$1.0M$14.0M$47.0M
Free Cash Flow$-12.0M$-15.0M$-16.0M$-30.0M$-30.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.33
EV / EBITDA-3.94
FCF Yield-13.55%
Quick Ratio16.00
Interest Coverage0.00
Return 1Y24.51%
Return 3Y—
Return 5Y—

Ownership

Insiders Held14.22%
Institutions Held41.96%
Institutions Float Held48.92%
Institutional HolderSharesReport Date
Beutel, Goodman & Company Ltd3,666,4652026-03-31
Affinity Asset Advisors, Llc1,589,0052026-03-31
Balyasny Asset Management LP1,350,0002026-03-31
Vivo Capital, LLC1,350,0002026-03-31
Scotia Capital Inc.1,342,1782026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AARD $5.73 -3.70% -1.79 $125.40M 0.00%
GNFTGenfit S.A. $8.95 +4.07% 261.07 $445.68M 0.00%
IVAInventiva S.A. $4.47 +1.59% -2.04 $232.36M 0.00%
MDWD $13.21 +1.15% -8.26 $169.69M 0.00%
NAUT $0.92 -4.40% -2.04 $117.01M 0.00%

About EPRX

EPRX is led by CEO James A. Helliwell, employs 33 people, headquartered in CA, publicly traded since 2024.

EPRX stock trades at $7.50 with a market capitalization of $251.10M. The stock is valued at a price-to-earnings (P/E) ratio of -7.36, price-to-book of 3.80, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $5.15 and $9.32, and currently trades 19.5% below its 52-week high.

On profitability, EPRX generates a return on equity (ROE) of -45.29%, return on capital employed of -43.18%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.50 -0.05% JNJ Drug Manufacturers - General $278.43 +1.17% ABBV Drug Manufacturers - General $260.30 -0.54% MRK Drug Manufacturers - General $152.34 +0.46% UNH Medical - Healthcare Plans $400.94 +0.32% NVS Drug Manufacturers - General $163.09 +0.39% AZN Drug Manufacturers - General $164.77 +1.94% AMGN Drug Manufacturers - General $444.12 +0.29% TMO Medical - Diagnostics & Research $618.43 +1.63% NVO Biotechnology $47.51 +1.58% ABT Medical - Devices $108.80 -1.51% GILD Drug Manufacturers - General $151.22 +1.08%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides